32 results about "Orodispersible film" patented technology

Described herein are orodispersible films comprising a film forming hydrophobic polymer, a disintegrant, a plasticizer and a stabilizer.

The invention relates to an oxiracetam oral dispersion membrane preparation and a preparation method thereof. The oxiracetam oral dispersion membrane preparation is prepared from a composite membrane forming material, a plasticizing agent, a filling agent and the like. The oxiracetam oral dispersion membrane preparation has the advantages that the preparation can be dissolved by less saliva in an oral cavity, and can be taken without using water, so that the taking is convenient; the easiness in vomiting is avoided after sticking onto a tongue, and the Oxiracetam oral preparation is suitable for patients with difficulty in swallowing; by utilizing mucosae to absorb, the first pass elimination effect is avoided, the bioavailability is improved, the medicine dosage is reduced, and the side effect is decreased. The preparation method has the advantages that the preparation technology is simple, and the preparation method is suitable for industrialized production.

The invention relates to an ibuprofen oral dispersing film agent which comprises ibuprofen, a film-forming material, purified water, plasticizer and the like, wherein the effective dosage of ibuprofen is selected to be 20mg, 30mg or 40mg. The product can be rapidly dispersed or dissolved in the oral cavity, and has the functions of analgesia, abatement of fever and inflammation reduction.

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.

The present disclosure relates to compositions for preparing an oral dispersible film comprising tadalafil or its pharmaceutically acceptable salt thereof, surfactant, plasticizer and sweetening agent; an oral dispersible film; and methods of preparing thereof. The oral dispersible film of the present disclosure can improve dissolution rate of the tadalafil without complicated processes and has superior stability compared to previous Cialis because generation of related compounds are inhibited regardless of existence of a packaging. Additionally, superior film properties comprising prevention of film breakage, securement of flexibility and prevention of oil leakage from film formulation can be maintained when comprising specific content of a polyethylene glycol 400 as the plasticizers.

The invention belongs to the field of medicinal preparations, and discloses an oral dissolving film preparation containing bulleyaconitine A and a preparation technology of the oral dissolving film preparation. The dissolving film contains bulleyaconitine A, polyacrylic resin II, a film forming substrate, a sweetening agent, a saliva irritant and essence. With the dissolving film, the tingling sensation and bitter taste of bulleyaconitine A can be well masked, and the preparation method is simple and feasible.

The invention discloses a method for preparing a levorotatory oxiracetam oral dispersible film preparation. The levorotatory oxiracetam oral dispersible film preparation is made by using a film forming material, a plasticizer, a filling agent, a saliva irritant, correctant and levorotatory oxiracetam as raw materials and through coating, drying and stripping by using a film coating and drying machine for a medicinal film. According to the method, the levorotatory oxiracetam oral dispersible film preparation is prepared by using a film coating machine for the medicinal film; the thickness, the coating speed and the drying temperature of the oral dispersible film preparation are strictly controlled; thus, the process is stabilized; the quality of a product is guaranteed; aspects of the brittlement, the disintegration time limit, the dissolution time and the like of the levorotatory oxiracetam oral dispersible film are enabled to be more beneficial to clinical application.

The invention provides a dextromethorphan hydrobromide oral dispersible film agent. The film agent comprises dextromethorphan hydrobromide, polacrilin or polacrilin potassium with grain diameter of 50-150mu m, a film forming agent, a plasticizer, a disintegrating agent, a wetting agent and water, wherein dextromethorphan hydrobromide and polacrilin or polacrilin potassium form a dextromethorphan hydrobromide compound, and the weight ratio of dextromethorphan hydrobromide to polacrilin or polacrilin potassium is 1:1-1:2, and preferably 1:1.3-1:1.5; the film forming agent comprises hydroxypropyl methylcellulose E3 and hydroxypropyl methylcellulose E50. The invention also provides a preparation method of the dextromethorphan hydrobromide oral dispersible film agent. The dextromethorphan hydrobromide oral dispersible film agent can well solve the problem of poor taste of dextromethorphan hydrobromide, is particularly suitable for children and old patients, and can remarkably improve the compliance of patients. An oral film tablet is nicer by an optimal preparation method.

The invention discloses a levo oxiracetam oral cavity dispersing film preparation. The levo oxiracetam oral cavity dispersing film preparation comprises 1 to 15 parts of levo oxiracetam, 85 to 95 parts of a film forming material, 5 to 10 parts of a plasticizer, and 2 to 5 parts of a saliva irritant. According to the preparation method, the above raw materials are subjected to full grinding and uniform mixing, and are delivered into a hot-melt lamination machine for extrusion so as to obtain a finished product. The appearance of the obtained levo oxiracetam oral cavity dispersing film preparation is complete, color is uniform, thickness is uniform, physical and chemical properties are stable, in oral cavity, the levo oxiracetam oral cavity dispersing film preparation can be dissolved with a small amount of saliva, taking of the levo oxiracetam oral cavity dispersing film preparation with water is not necessary, the levo oxiracetam oral cavity dispersing film preparation is convenient to eat, and the preparation method is simple, and is suitable for industrialized production.

The invention relates to an loratadine oral dispersible film agent. The loratadine oral dispersible film agent is prepared from the following raw and auxiliary materials in percentage by mass of 25-40% of loratadine, 0.3-1% of polysorbate 80, 1-10% of plasticizer, 0.001-0.02% of glyceride fatty acid, 2-5% of povidone K30, 22-35% of hypromellose-E5, 10-25% of hydroxypropyl cellulose-SL, 1-8% of maltose, 0.5-5% of saccharin sodium, and 1-6% of opacifier; and the particle size X90 of loratadine is less than or equal to 10 mu m. The preparation process disclosed by the invention is simple and controllable, and is suitable for industrial mass production; the prepared oral dispersible film agent has significantly improved tensile strength, disintegration speed, taste and stability, has the advantages of high drug loading capacity, small volume, convenience in carrying, dosage control and administration, and rapid disintegration in the oral cavity without drinking water, realizes rapid release of active ingredients of the drug, has good taste and is easy to accept, and compliance and the safety of children medication are improved.

The invention relates to a new composite based on hydroxypropyl-beta-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-beta-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-beta-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.

The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.

The invention discloses a method for preparing an oxiracetam oral dispersible film preparation. The method comprises the following steps of sufficiently grinding and uniformly mixing 1 to 15 parts of oxiracetam, 80 to 95 parts of film forming material, 5 to 10 parts of plasticizer, 2 to 5 parts of saliva irritant and 1 to 3 parts of sweetener, sending a mixture to a hot melting zone through a feeding zone of a hot-melt film laminator, hot melting the mixture at 70 to 95 DEG C, continuously outputting the molten mixture through a proportioning zone, pouring the molten mixture into a mold, and cooling the mixture to form the film preparation. According to the method, the film forming material of specific type and use level is selected to be combined with the plasticizer; thus, technical problems that the film preparation is easy to break, is poor in strength and toughness, is slow to disintegrate, is longer in dissolution time and is not beneficial to the absorption of a medicine, and the like, are solved; the made oxiracetam oral dispersible film preparation is enabled to be good in demolding performance; a medicinal film is flexible, is uneasy to break, and is short in the dissolution time.

The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amount comprised between 0.5 and 6% by weight; d) an active ingredient for food or therapeutic use in an amount between 0.05 and 30% by weight, characterised in that it contains a homopolymer or a copolymer of vinyl acetate in a quantity comprised between 2 and 10% by weight where the percentages are calculated on the total weight of said film